id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-332967-fo12lbvs	Taher, Ali T.	Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations	2020-05-21		.txt	text/plain	1368	85	47	general population, patients with hemoglobin disorders such as sickle cell disease (SCD) or thalassemia are expected to be more severely affected by COVID-19 due to their preexisting chronic morbidities. Patients had a history of respiratory complications, such as acute chest syndrome (ACS), asthma, or pulmonary embolism, which may be potential risk factors for progressive COVID-19 pulmonary disease in patients with SCD. 2, 6 In areas where severe blood shortages are expected due to the pandemic, a low dose of hydroxyurea is recommended in all pediatric patients with sickle cell anemia, who receive regular blood transfusion therapy for primary or secondary stroke prevention. 7 Noteworthy, a treatment with one single dose of tocilizumab (8 mg/kg) was successfully used to treat an adult SCD patient with pneumonia; it was related to COVID-19 infection associated with ACS. COVID-19 infection in patients with sickle cell disease	./cache/cord-332967-fo12lbvs.txt	./txt/cord-332967-fo12lbvs.txt